Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443655 | 1.00 | HSD17B10 (0.47) | HSD17B10NR1H2NR1H3PTPN1FKBP1A | |
| SCHEMBL26353928 | 1.00 | HSD17B10 (0.47) | HSD17B10NR1H2NR1H3PTPN1FKBP1A | |
| SCHEMBL190042 | 0.90 | HSD17B10 (0.58) | HSD17B10FKBP1ASMN1; SMN2NPC1LMNA | |
| SCHEMBL883030 | 0.90 | HSD17B10 (0.58) | HSD17B10FKBP1ASMN1; SMN2NPC1LMNA | |
| SCHEMBL1486184 | 0.90 | HSD17B10 (0.58) | HSD17B10FKBP1ASMN1; SMN2NPC1LMNA | |
| SCHEMBL7328713 | 0.89 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL18555624 | 0.89 | NR1H2 (0.42) | HSD17B10NR1H2NR1H3PTPN1FKBP1A | |
| SCHEMBL18555530 | 0.89 | NR1H2 (0.42) | HSD17B10NR1H2NR1H3PTPN1FKBP1A | |
| SCHEMBL26136953 | 0.89 | NR1H2 (0.42) | HSD17B10NR1H2NR1H3PTPN1FKBP1A | |
| SCHEMBL88684 | 0.89 | FKBP1A (0.58) | HSD17B10FKBP1ASMN1; SMN2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-4536224-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | Blossomhill Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119421709-A | Indazole-containing macrocyclic compounds and uses thereof | 荣山医药股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023240138-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-8415340-B2 | Triazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100197654-A1 | TRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| EP-2175933-A1 | TRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009015254-A1 | TRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-29 | — | — | WO | disclosed |
| US-4902684-A | Benzazepine and benzothiazepine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1990-02-20 | — | — | US | disclosed |
| WO-1989012633-A1 | BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | E.R. SQUIBB & SONS, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | HSD17B10 4428/4885NR1H2 4436/4885NR1H3 3972/4885 |
| US-20100197654-A1 | TRIAZINE KINASE INHIBITORS | ABL1, STK25, FLT3 | HSD17B10 2672/4885NR1H2 3280/4885NR1H3 3916/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | HSD17B10 1037/4885NR1H2 1173/4885NR1H3 1208/4885 |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | HSD17B10 2712/4885NR1H2 3333/4885NR1H3 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.